News
PTHS
6.51
-4.82%
-0.33
Weekly Report: what happened at PTHS last week (1109-1113)?
Weekly Report · 2d ago
Pelthos Therapeutics Price Target Cut to $21.00/Share From $48.00 by Piper Sandler
Dow Jones · 5d ago
Piper Sandler Reiterates Overweight on Pelthos Therapeutics, Lowers Price Target to $21
Benzinga · 5d ago
Pelthos Therapeutics Price Target Cut to $59.00/Share From $64.00 by Oppenheimer
Dow Jones · 5d ago
Pelthos Therapeutics Is Maintained at Outperform by Oppenheimer
Dow Jones · 5d ago
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $59
Benzinga · 5d ago
Analysts Offer Insights on NA Companies: Builders Firstsource (BLDR), Pelthos Therapeutics (PTHS) and Evommune, Inc. (EVMN)
TipRanks · 5d ago
Analysts Offer Insights on NA Companies: Pelthos Therapeutics (PTHS) and Lineage Therap (LCTX)
TipRanks · 5d ago
Pelthos Therapeutics price target lowered to $59 from $64 at Oppenheimer
TipRanks · 5d ago
Pelthos Therapeutics price target lowered to $21 from $48 at Piper Sandler
TipRanks · 5d ago
Pelthos Therapeutics downgraded to Neutral from Buy at Alliance Global
TipRanks · 5d ago
Restrictive 2026 Merger Deal Seen Curbing Pelthos Therapeutics’ Capital Raising and Strategic Flexibility
TipRanks · 5d ago
Pelthos Therapeutics Earnings Call Signals Growth and Expansion
TipRanks · 5d ago
Pelthos Therapeutics Q3 2026 Earnings Call Transcript
Benzinga · 6d ago
Pelthos Therapeutics GAAP EPS of -$2.04 beats by $1.21, revenue of $15.2M misses by $1.7M
Seeking Alpha · 6d ago
Pelthos Therapeutics reports Q3 EPS ($2.04), consensus ($3.33)
TipRanks · 6d ago
Pelthos Therapeutics Inc. (PTHS) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 6d ago
Press Release: Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
Dow Jones · 6d ago
Press Release: Pelthos Therapeutics Announces -2-
Dow Jones · 6d ago
Alvotech (ALVO) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 11/11 21:55
More
Webull provides a variety of real-time PTHS stock news. You can receive the latest news about Pelthos Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About PTHS
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.